<DOC>
	<DOCNO>NCT00235885</DOCNO>
	<brief_summary>The purpose study assess safety clinical efficacy adalimumab active psoriatic arthritis ( PsA ) subject adalimumab add insufficient standard therapy include patient fail TNF therapy</brief_summary>
	<brief_title>Safety Efficacy Study Adalimumab Patients With Active Psoriatic Arthritis ( PsA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Males female &gt; 18 year age Active PsA &gt; 3 tender &gt; 3 swollen joint despite standard therapy Unsatisfactory response intolerance least one prior ongoing DMARD ( study enrollment must accordance current national guideline treatment PsA TNF inhibitor ) A negative serum pregnancy test ( serum HCG ) woman childbearing potential prior start treatment . Use reliable method contraception female patient childbearing potential Able willing selfadminister sc injection suitable person administer sc injection Able willing give write informed consent comply protocol Prior treatment investigational agent within 30 day five half life product , whichever longer Treatment within last 2 month infliximab within last 3 week etanercept Treatment within last 4 week combination MTX leflunomide Treatment within last 4 week combination cyclosporine DMARDSubject receive UVA phototherapy ( include PUVA within 2 week prior screen ) History cancer lymphoproliferative disease successfully completely treat squamous cell basal cell carcinoma skin cervical dysplasia History current active acute inflammatory joint disease origin PsA Comorbidities ( uncontrolled diabetes , unstable ischemic heart disease , CHF , active IBD , stroke within 3 month , chronic leg ulcer condition would put subject risk participation protocol Positive serology hepatitis B C History positive HIV status Persistent recurrent infection severe infection require hospitalization treatment iv antibiotic within 30 day , oral antibiotic within 14 day prior enrollment Females pregnant breastfeed History clinically significant drug alcohol abuse last year Previous diagnosis sign central nervous system demyelinate disease History tuberculosis , histoplasmosis listeriosis Subjects latent TB risk factor activation latent TB initiate TB prophylaxis prior first adalimumab treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>adalimumab</keyword>
</DOC>